Clinical Trial Update: Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A phase 3 clinical trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment for EGFR-mutated advanced non-squamous non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Carcinoma
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN